2008-08-13 05:00:00
IRVINE, Calif., Aug. 13 /EMWNews/ -- Endocare, Inc. (Nasdaq: ENDO) announced today that its Board of Directors has unanimously rejected the unsolicited proposal from HealthTronics, Inc. (Nasdaq: HTRN) to purchase all of the outstanding shares of Endocare for $2.28 per share. After careful evaluation, the Board determined that the proposal is inadequate and not in the best interests of Endocare's stockholders.
About Endocare
Endocare, Inc. -- http://www.endocare.com -- is an innovative medical
device company focused on the development of minimally invasive
technologies for tissue and tumor ablation. Endocare has initially
concentrated on developing technologies for the treatment of prostate
cancer and believes that its proprietary technologies have broad
applications across a number of markets, including the ablation of tumors
in the kidney, lung and liver and palliative intervention (treatment of
pain associated with metastases).
Investor Contact: Media Contact: For Additional
Matt Clawson Len Hall Information:
Allen & Caron, Inc. Allen & Caron, Inc. Craig T. Davenport, CEO
(949) 474-4300 (949) 474-4300 Michael R. Rodriguez, CFO
[email protected] [email protected] Endocare, Inc.
http://www.allencaron.com http://www.allencaron.com (949) 450-5400
http://www.endocare.com
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89
Get Unlimited Organic Website Traffic to your Website
TheNFG.com now offers Organic Lead Generation & Traffic Solutions
